Immunai

Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system.

Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment.

The company is located in New York City, San Francisco, and Tel Aviv, Israel.

Immunai headquartered in New York, New York, United States, North America, operates in the Biotechnology, Artificial Intelligence (AI), Machine Learning, Analytics, Therapeutics sector. The company focuses on Biotechnology and has secured $17.7B in funding across 60 round(s). With a team of 101-250 employees, Immunai is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Immunai, raised $215.0M. Discover more about their projects, partnerships, and impact on our platform.